Top news of the day from across the health care landscape.
The US Preventive Services Task Force (USPSTF) is recommending that physicians offer pre-exposure prophylaxis (PrEP) to those at high risk of HIV, STAT reported. According to the article, the USPSTF noted that it found “adequate epidemiologic data” on risk factors that can be used to identify individuals who are at high risk of acquiring HIV. The move could require insurance companies to expand coverage for the medicine if the recommendation is adopted, the article reported.
On Tuesday, the US Court of Appeals for the Federal Circuit allowed generic company Dr. Reddy’s Laboratories to sell its generic version of Suboxone film, Indivior’s treatment for opioid dependence, Reuters reported. According to the article, the US appeals court lifted a preliminary injunction that blocked Dr. Reddy’s from selling the generic. In a statement, Indivior announced it would continue to pursue ongoing US patent litigation against Dr. Reddy’s that seeks to block sales of the generic version, the article reported.
A recent study suggests that a US online tool may help men with prostate cancer better understand their treatment choices, Reuters reported. According to the article, the researchers used data on treatment choices made by 5016 men diagnosed with prostate cancer to develop a web-based tool that predicts the most likely treatment choice based on what other men in similar circumstances have chosen. For men who have early-stage tumors, the tool focuses on aspects of prostate cancer diagnoses, patients’ age and weight, and any history of heart attack or diagnosis of diabetes, the article reported.